2025年全年，公司实现销售额443亿美元，按报告基准增长5.7%。公司连续血糖监测业务第四季度销售 额达到20亿美元，按报告基准增长15.0%。 展望未来，公司预计2026年全年有机销售额增长6.5%至7.5%，调整后每股收益为5.55至5.80美元，中值 增长10%。公司预计将在2026年第二季度完成对Exact Sciences的战略收购，从而进军快速增长的癌症诊 断市场。 智通财经APP获悉，周四，雅培(ABT.US)盘前跌超7%，报112.02美元。消息面上，该公司报告称，2025 年第四季度销售额为114.6亿美元，比预期少了 3.4 亿美元，按报告基准增长4.4%，排除COVID-19检测 的影响后有机增长3.8%。第四季度调整后每股收益(EPS)达到1.50美元，同比增长12%，而2025年全年 调整后每股收益增长10%至5.15美元。公司的医疗器械部门引领增长，增幅达12.3%，主要受益于糖尿 病护理和电生理领域的强劲表现。 ...

2025年全年，公司实现销售额443亿美元，按报告基准增长5.7%。公司连续血糖监测业务第四季度销售 额达到20亿美元，按报告基准增长15.0%。 周四，雅培(ABT.US)盘前跌超7%，报112.02美元。消息面上，该公司报告称，2025年第四季度销售额 为114.6亿美元，比预期少了3.4亿美元，按报告基准增长4.4%，排除COVID-19检测的影响后有机增长 3.8%。第四季度调整后每股收益(EPS)达到1.50美元，同比增长12%，而2025年全年调整后每股收益增 长10%至5.15美元。公司的医疗器械部门引领增长，增幅达12.3%，主要受益于糖尿病护理和电生理领 域的强劲表现。 展望未来，公司预计2026年全年有机销售额增长6.5%至7.5%，调整后每股收益为5.55至5.80美元，中值 增长10%。公司预计将在2026年第二季度完成对Exact Sciences的战略收购，从而进军快速增长的癌症诊 断市场。 ...

Fourth-quarter and full-year 2025 results | Adjusted diluted EPS | | | | --- | --- | --- | | Fourth quarter | $1.501 | ↑12% | | Full year | $5.152 | % ↑10 | | W orldwide sales | Organic* sales growth for underlying base business** | 5 Full-year 2026 guidance | | $11.5B | ↑3.8%3 | 6.5% to 7.5% | | Fourth quarter | | Organic sales growth | | $44.3B | ↑6.7%4 | $5.55 to $5.80 | | Full year | | Adjusted diluted EPS | Key business units | Fourth-quarter sales Expanding in the fast-growing pulsed field ablation (P ...

格隆汇1月22日｜雅培公布2025年第四季度业绩，总营收为114.6亿美元，按报告基准同比增长4.4%，低 于分析师平均预期的118亿美元，主要是因为诊断业务因新冠检测需求急剧下降，且受到特朗普政府冻 结对外援助的影响；调整后每股收益为1.5美元，同比增长12%。展望2026年，雅培预计全年有机销售 额将增长6.5%至7.5%，调整后每股收益将介于5.55至5.8美元之间。 ...

Key TakeawaysThe European Central Bank (ECB) expressed widespread concern regarding financial stability risks and noted a fragile economic recovery in the Euro area during its December 18th monetary policy meeting, despite staff projections strengthening confidence in the medium-term outlook.China and the United States have reportedly signed off on a US spinoff of the popular social media platform TikTok, potentially resolving significant geopolitical and data security concerns.Abbott Laboratories (ABT) ann ...

Abbott Laboratories (ABT) lost ~5% in the premarket on Thursday after the MedTech giant reported lower-than-expected revenue for Q4 2025 following underperformance in its Nutrition segment. The company recorded $11.5B in net sales for the quarter with ~4% YoY growth, missing the $11.8B projected by ...

Abbott reports fourth-quarter sales that miss analysts' estimates. ...

Earnings Per Share (EPS) - Fourth-quarter GAAP diluted EPS was $1.01, and adjusted diluted EPS was $1.50, reflecting a growth of 12%[3] - Full-year 2025 GAAP diluted EPS was $3.72, and adjusted diluted EPS was $5.15, reflecting a growth of 10%[3] - Abbott expects full-year 2026 adjusted diluted EPS to be between $5.55 and $5.80, indicating a 10% growth at the midpoint[3] - In Q4 2025, Abbott reported a net earnings of $1.776 billion, which adjusted to $2.630 billion after specified items, resulting in a diluted earnings per share of $1.01 and $1.50 respectively[37] Sales Performance - Full-year 2025 sales reached $44.3 billion, an increase of 5.7% on a reported basis and 5.5% on an organic basis[3] - Fourth-quarter sales increased by 4.4% on a reported basis and 3.0% on an organic basis, or 3.8% when excluding COVID-19 testing-related sales[3] - In Q4 2025, total worldwide sales reached $11.459 billion, a 4.4% increase from $10.974 billion in Q4 2024[27] - For the full year 2025, total worldwide sales were $44.328 billion, up 5.7% from $41.950 billion in 2024[32] - In Q4 2025, U.S. sales were $2.605 billion, reflecting a 10.7% increase compared to Q4 2024[17] - International sales in Q4 2025 totaled $3.070 billion, marking a 13.7% increase year-over-year[17] - The Diabetes Care segment reported sales of $2.0 billion in Q4 2025, growing 15.0% on a reported basis[18] - Abbott's international revenue for 2025 was $27.202 billion, up 6.1% from $25.627 billion in 2024[49] Future Projections - Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%[3] - The company plans to continue focusing on market expansion and new product development as part of its growth strategy[52] Expenses and Margins - Abbott's R&D expenses for 2025 were $2.942 billion, adjusted to $2.830 billion, showing a slight increase from $2.844 billion in 2024[41] - The company's SG&A expenses for 2025 were reported at $12.332 billion, adjusted to $12.020 billion, compared to $11.697 billion in 2024[41] - The gross margin for Q4 2025 was $6.115 billion, adjusted to $6.543 billion after accounting for specified items, reflecting an increase from Q4 2024's adjusted gross margin of $6.240 billion[37][38] - Gross margin for the twelve months ended December 31, 2025, was $1,824 million, with a contribution of $1,682 million from intangible amortization[57] Net Earnings - Net earnings for Q4 2025 were $1.776 billion, compared to $9.229 billion in Q4 2024, with significant adjustments impacting the figures[29] - For the full year 2025, Abbott's net earnings were reported at $6.524 billion, adjusted to $9.040 billion, with diluted earnings per share increasing from $3.72 to $5.15[41] - Net earnings for the same period were $2,516 million, resulting in diluted earnings per share of $1.43[57] - For the twelve months ended December 31, 2024, net earnings were reported as a loss of $5,202 million, leading to diluted earnings per share of $(2.97)[60] Acquisitions and Approvals - Abbott announced an agreement to acquire Exact Sciences to enter the cancer diagnostics market, with the transaction expected to close in Q2 2026[3] - Abbott received FDA approval for its Volt™ PFA System and CE Mark for its TactiFlex™ Duo Ablation Catheter, enhancing its Electrophysiology leadership[3] Tax and Other Items - In Q4 2025, the effective tax rate excluding specified items was 14.8%, compared to 15.0% in Q4 2024[44] - The specified items in Q4 2025 included $422 million in intangible amortization and $306 million in other net expenses related to restructuring and acquisitions[37][50] - The company recognized a tax benefit of approximately $610 million due to the resolution of various tax positions related to prior years[58] - Acquisition-related expenses included integration costs directly related to integrating acquired businesses[55]

Core Insights - Abbott missed Wall Street estimates for quarterly revenue, primarily due to weakness in its diagnostic business, which has been affected by a significant decline in COVID-19 testing demand [1] Group 1: Financial Performance - The company's quarterly revenue fell short of expectations, indicating challenges in maintaining growth in its diagnostic segment [1] - The decline in COVID-19 testing demand has led to volatility in Abbott's diagnostic business, impacting overall revenue performance [1] Group 2: Market Conditions - The current market conditions reflect a sharp decrease in demand for COVID-19 testing, which has been a critical factor in Abbott's recent financial results [1] - The freeze on certain diagnostic services has further contributed to the challenges faced by the company in this segment [1]

Core Insights - Abbott reported strong financial results for Q4 2025, with total worldwide sales reaching $11.459 billion, a 4.4% increase from Q4 2024 [28] - The company achieved double-digit earnings per share growth, with adjusted diluted EPS of $1.50, reflecting a 12% increase [5] - Abbott's full-year 2025 sales totaled $44.328 billion, marking a 5.7% increase compared to 2024 [28] Financial Performance - Q4 2025 sales increased 4.4% on a reported basis and 3.0% on an organic basis, with a 3.8% increase when excluding COVID-19 testing-related sales [5][28] - Full-year 2025 GAAP diluted EPS was $3.72, while adjusted diluted EPS was $5.15, reflecting a 10% growth [5][28] - Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5% and adjusted diluted EPS of $5.55 to $5.80 [5][22] Segment Performance - In Q4 2025, Nutrition sales decreased by 8.9% on a reported basis and 9.1% on an organic basis, primarily due to lower sales volumes [9][10] - Diagnostics sales in Q4 2025 were $2.457 billion, a decrease of 2.5% on a reported basis and 3.6% on an organic basis [12][28] - Medical Devices sales increased by 12.3% on a reported basis and 10.4% on an organic basis, driven by strong growth in Electrophysiology and Diabetes Care [19][20] Strategic Developments - Abbott announced an agreement to acquire Exact Sciences, positioning the company to enter the cancer diagnostics market [5] - The company received FDA approval for its Volt™ PFA System and CE Mark for its TactiFlex™ Duo Ablation Catheter, enhancing its Electrophysiology portfolio [5][10] Dividend Information - Abbott declared a quarterly dividend of $0.63 per share, marking the 408th consecutive quarterly dividend and reflecting a commitment to returning value to shareholders [24]